Express Pharma

Panel Discussion on ‘Formulation and delivery of vaccines and biologics’ | FDD Conclave 2022

1 126


Panelists in this video:
+ Dr Rajendra Lingala, VP & Head R&D, Indian Immunologicals
+ Dr Vinod Pantula, Head-Vaccines, Dr Reddy’s Laboratories
+ Dr Prasanna Devaraneni, AVP and Head-Biopharma, Vimta Labs

Moderator:
Dr Ramesh Matur, Sr VP and Head, Vaccines R&D, Biological E

Key Highlights:
+ Every vaccine is customised to a disease: Dr Ramesh Matur, Sr VP and Head, Vaccines R&D, Biological E

+ It is the disease by which we target the route of a vaccine. We are working on an intranasal vaccine for COVID-19: Dr Rajendra Lingala, VP and Head, R&D, Indian Immunologicals

+ In India, there are only a handful of vaccine companies. We have to move away from traditional methods and follow innovative methods in future: Dr Vinod Pantula, Head-Vaccines, Dr Reddy’s Laboratories

+ There are various scenarios that bring challenges for formulations. Preserving the structure of a protein is one such challenge: Dr Prasanna Devaraneni, AVP and Head – Biopharma, Vimta Labs

+ Needle-free technology for delivering vaccines is in development, it’s a next-generation thing: Dr Rajendar Burki, Associate VP, R&D, Biological E

- Advertisement -

1 Comment
  1. soundos says

    thank you for providing such a wonderfull article